94 related articles for article (PubMed ID: 7755392)
1. [Low-dose cytarabine ocfosfate therapy in an elderly acute myelogenous leukemia].
Hamaoka R; Jozaki K; Amano T; Itoh H; Imai Y; Nishikawa M; Kurokawa M; Yonezawa T; Chinen Y
Gan To Kagaku Ryoho; 1995 May; 22(6):819-22. PubMed ID: 7755392
[TBL] [Abstract][Full Text] [Related]
2. [Successful treatment of acute myelomonocytic leukemia developed from MDS with cytarabine ocfosfate (SPAC)].
Wake A; Takazawa A; Serino Y; Tonai S; Nakanishi M; Murakami S; Ogawa R; Nagata K; Mori N; Nakata K
Gan To Kagaku Ryoho; 1995 Feb; 22(3):395-8. PubMed ID: 7880111
[TBL] [Abstract][Full Text] [Related]
3. [Successful treatment of acute myelogenous leukemia in an elderly patient with cytarabine ocfosfate].
Inaba T; Shimazaki C; Tatsumi T; Yamagata N; Hirata T; Goto H; Fujita N; Nakagawa M; Fujita N; Miyazaki S
Gan To Kagaku Ryoho; 1994 Mar; 21(4):535-8. PubMed ID: 8129396
[TBL] [Abstract][Full Text] [Related]
4. [A pharmacokinetic study of the value of oral cytarabine ocfosfate in the treatment of hematological malignancies].
Ueda Y; Mori S; Ito T; Maesako Y; Konishi H; Yagiri Y
Rinsho Ketsueki; 1998 May; 39(5):348-54. PubMed ID: 9637884
[TBL] [Abstract][Full Text] [Related]
5. [Treatment of refractory hematologic malignancies by combination of cytarabine ocfosfate and etoposide].
Kiyama Y; Suzuki G; Masauzi N; Ohizumi H; Kobayashi N; Ogasawara M; Naohara T; Saito M; Higa T; Kasai M
Gan To Kagaku Ryoho; 1996 Oct; 23(12):1717-20. PubMed ID: 8886052
[TBL] [Abstract][Full Text] [Related]
6. [Hypoplastic leukemia successfully treated by oral administration with cytarabine ocfosfate].
Okuyama Y; Kitazume K; Iwabe K; Usuki K; Urabe A
Rinsho Ketsueki; 1994 Jun; 35(6):593-7. PubMed ID: 8078195
[TBL] [Abstract][Full Text] [Related]
7. [Successful treatment of refractory anemia with excess of blasts in transformation with cytarabine ocfosfate].
Takeuchi M; Kojima K; Takaba S; Isokawa M; Tanimizu M; Kimura F; Ohmoto E; Harada M
Gan To Kagaku Ryoho; 1995 Jan; 22(1):141-4. PubMed ID: 7826071
[TBL] [Abstract][Full Text] [Related]
8. [Oral administration of cytarabine ocfosfate and ondansetron hydrochloride in patients with acute myeloid leukemia who can not be treated with intensive chemotherapy:--attempt to make their quality of life better].
Yano K; Matsui H; Fujisawa S
Gan To Kagaku Ryoho; 1998 Feb; 25(3):427-30. PubMed ID: 9492840
[No Abstract] [Full Text] [Related]
9. Treatment of acute myeloid leukemia and myelodysplastic syndrome with orally administered cytarabine ocfosfate and granulocyte colony-stimulating factor.
Okumura H; Yoshida T; Takamatsu H; Katoh T; Murashima M; Watanabe A; Yamauchi H; Matano S; Chuhjo T; Takeshima M; Kaya H; Ohtake S; Nakamura S; Matsuda T
Int J Hematol; 1997 Apr; 65(3):263-8. PubMed ID: 9114597
[TBL] [Abstract][Full Text] [Related]
10. [A combination chemotherapy with cytarabine ocfosfate, low dose etoposide, and G-CSF for the treatment of high risk MDS (RAEB, RAEBt)--a pilot study].
Hara M; Kojima K; Azuma T; Narumi H; Shinagawa K
Rinsho Ketsueki; 1998 Apr; 39(4):314-6. PubMed ID: 9597900
[TBL] [Abstract][Full Text] [Related]
11. [Plasma concentration of cytosine arabinoside (Ara-C) in the elderly patients with hematological malignancy treated by Ara-C or cytarabine ocfosfate (SPAC)].
Tsutsumi H; Kumakawa T; Hirai M; Kikukawa M; Arie Y; Mori M; Kodo H; Nakamura N; Murai Y; Mizutani R
Nihon Ronen Igakkai Zasshi; 1995 Mar; 32(3):190-4. PubMed ID: 7596061
[TBL] [Abstract][Full Text] [Related]
12. Bone marrow cytogenetic complete remission achieved by interferon-alpha plus cytarabine ocfosfate therapy in a patient with chronic myelogenous leukemia during extramedullary blast crisis.
Gotoh A; Miyazawa K; Uchida Y; Sashida G; Kawakubo K; Kuriyama Y; Ohyashiki K
Int J Hematol; 2002 Feb; 75(2):191-4. PubMed ID: 11939268
[TBL] [Abstract][Full Text] [Related]
13. [A case of complete remission from acute unclassified leukemia achieved by using a prodrug of ara C, stearyl-ara-CMP (YNK01)].
Nishikawa M; Morita K; Komada F; Uemura Y; Kageyama S; Minami N; Deguchi K; Shirakawa S
Gan No Rinsho; 1990 Oct; 36(12):2204-9. PubMed ID: 2232191
[TBL] [Abstract][Full Text] [Related]
14. Clinical pharmacology of 1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate, an orally administered long-acting derivative of low-dose 1-beta-D-arabinofuranosylcytosine.
Ueda T; Kamiya K; Urasaki Y; Wataya S; Kawai Y; Tsutani H; Sugiyama M; Nakamura T
Cancer Res; 1994 Jan; 54(1):109-13. PubMed ID: 8261429
[TBL] [Abstract][Full Text] [Related]
15. [A new antileukemic drug, cytarabine ocfosfate].
Tsukagoshi S
Gan To Kagaku Ryoho; 1993 Sep; 20(12):1877-83. PubMed ID: 8379682
[TBL] [Abstract][Full Text] [Related]
16. [Five cases of myelodysplastic syndrome treated with cytarabine ocfosfate].
Nishi T; Funasako M; Hata N; Andoh K; Itoh Y; Ono H; Itoh K; Sato Y; Sato H; Taniji M; Nakai S; Ueda A; Fujimoto H; Ohata M
Gan To Kagaku Ryoho; 1996 Sep; 23(10):1331-4. PubMed ID: 8831748
[TBL] [Abstract][Full Text] [Related]
17. [Therapy-related acute non-lymphocytic leukemia (M2) with 7;11 chromosome translocation induced into complete remission by low dose cytosine arabinoside and cytarabine ocfosfate therapy].
Shikoshi K; Shikoshi K; Niitsu N; Takada M; Umeda M
Nihon Ronen Igakkai Zasshi; 1994 Jun; 31(6):468-71. PubMed ID: 8078212
[TBL] [Abstract][Full Text] [Related]
18. [Effects of cytarabine ocfosfate on colony-stimulating factor in myelodysplastic syndrome with monosomy 7].
Masumoto A; Ohbayashi Y; Kawada H; Arimori K; Sasao T; Ogawa Y; Fujiwara H; Fukuda R; Watanabe S; Umeda Y
Rinsho Ketsueki; 1994 Jun; 35(6):603-8. PubMed ID: 7521405
[TBL] [Abstract][Full Text] [Related]
19. [Complete remission by cytarabine ocfosfate plus G-CSF therapy in a patient with hypoplastic RAEB-T].
Kadowaki I; Sasaki O; Sasaki T; Ishizawa K; Kimura J; Nomura J; Furuyama K; Harigae H; Shishido T; Okuda M
Gan To Kagaku Ryoho; 1995 Jan; 22(1):145-7. PubMed ID: 7529978
[No Abstract] [Full Text] [Related]
20. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
